CHD5 Inhibitors
The class of CHD5 Inhibitors is characterized by its capacity to interfere with the chromatin remodeling functions of the CHD5 protein. These compounds achieve this through a variety of mechanisms, primarily revolving around the modulation of histone post-translational modifications and chromatin structure.Compounds such as 5-Azacytidine, Trichostatin A, Vorinostat, Romidepsin, and Mocetinostat can directly modify the acetylation or methylation status of histones. These modifications can affect the conformation of chromatin and the accessibility of DNA, thus influencing the ability of CHD5 to interact with and remodel chromatin.
In a similar vein, JQ1 and I-BET762, inhibitors of BET bromodomains, can modulate the recognition of acetylated histones. These compounds can thereby impact the interaction of chromatin remodeling proteins, including CHD5, with chromatin. Additionally, compounds like EPZ-6438, GSK126, UNC1999, and DZNep, which are inhibitors of the histone methyltransferase EZH2, can modify histone methylation status. Such alterations can influence the chromatin structure and the associated activities of CHD5. Lastly, BIX-01294, an inhibitor of G9a and GLP histone methyltransferases, can affect histone methylation, thereby influencing the activity of CHD5.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor that can alter DNA methylation status, affecting the substrate availability for CHD5 and thereby influencing its activity. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Vorinostat is another histone deacetylase inhibitor that can modify histone acetylation and chromatin conformation, thereby influencing CHD5 activity. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $214.00 $622.00 | 1 | |
Romidepsin is an inhibitor of histone deacetylase which can affect the acetylation status of histones, thereby influencing chromatin structure and CHD5 function. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $210.00 $242.00 $1434.00 | 2 | |
Mocetinostat is a histone deacetylase inhibitor that can modify the acetylation status of histones and influence the chromatin structure and CHD5 activity. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
JQ1 is a BET bromodomain inhibitor that can modulate the recognition of acetylated histones, potentially affecting the chromatin remodeling activities of CHD5. | ||||||
GSK 525762A | 1260907-17-2 | sc-490339 sc-490339A sc-490339B sc-490339C sc-490339D | 5 mg 10 mg 50 mg 100 mg 1 g | $300.00 $540.00 $940.00 $1680.00 $5900.00 | ||
I-BET762 is a BET bromodomain inhibitor that can modulate the recognition of acetylated histones, thereby affecting the chromatin remodeling activities of CHD5. | ||||||
EPZ6438 | 1403254-99-8 | sc-507456 | 1 mg | $66.00 | ||
EPZ-6438 is an EZH2 inhibitor that can affect histone methylation and influence the chromatin remodeling activities of CHD5. | ||||||
GSK126 | 1346574-57-9 | sc-490133 sc-490133A sc-490133B | 1 mg 5 mg 10 mg | $90.00 $238.00 $300.00 | ||
GSK126 is another EZH2 inhibitor that can affect histone methylation status, thereby influencing the chromatin remodeling activities of CHD5. | ||||||
UNC1999 | 1431612-23-5 | sc-475314 | 5 mg | $142.00 | 1 | |
UNC1999 is an inhibitor of EZH2 and EZH1 that can affect histone methylation status and influence the activity of CHD5. | ||||||
3-Deazaneplanocin, HCl salt | 120964-45-6 | sc-351856 sc-351856A sc-351856B | 1 mg 5 mg 10 mg | $251.00 $600.00 $918.00 | 2 | |
DZNep is an inhibitor of EZH2 that can affect histone methylation status and influence the activity of CHD5. | ||||||